Two‐year outcomes of the ARTISAN‐SNM study for the treatment of urinary urgency incontinence using the Axonics rechargeable sacral neuromodulation system

Pezzella, Andrea; McCrery, Rebecca; Lane, Felicia; Benson, Kevin; Taylor, C. B.; Padron, Osvaldo F.; Blok, Bertil; Wachter, Stefan De; Gruenenfelder, Jennifer; Pakzad, Mahreen; Perrouin-Verbe, M.-A.; Kerrebroeck, Philip Van; Mangel, Jeffrey; Peters, Kenneth M.; Kennelly, Michael; Shapiro, A. M. James; Lee, Una; Comiter, Craig V.; Mueller, Margaret; Goldman, Howard B.

doi:10.1002/nau.24615

Cited by 22 publications

(8 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Additional studies with larger sample sizes are required to assess the validity of these results. During the 2-year follow-up of a new rechargeable SNM device (Axonics System), only 16% (13/51) of the patients had adverse reactions 17 . This ratio is similar to the complication rate of the BetterStim system group in this study, and both are clinical trials, suggesting that adequate patient education and management may play a positive role in reducing the incidence of adverse events.…”

Section: Discussionmentioning

confidence: 99%

Sacral neuromodulation for overactive bladder using the InterStim and BetterStim systems

Meng

Tian

Zhang

et al. 2022

Sci Rep

View full text Add to dashboard Cite

This study aimed to evaluate differences in the clinical outcomes of different sacral neuromodulation systems (InterStim and BetterStim) used in the treatment of overactive bladder. Data from a previously established database of sacral neuromodulation in China (the InterStim system) and a 2020 clinical trial of the BetterStim system were screened. Patients with overactive bladder undergoing stage II implanted pulse generator implantation were selected for analysis and divided into InterStim and BetterStim system groups. Voiding diaries and subjective scores obtained preoperatively, after stage I tined-lead implantation (experience period), and after stage II implanted pulse generator implantation were compared between the two groups. This study included 113 patients with overactive bladder (43, InterStim system group; 70, BetterStim system group). Voiding diaries and subjective scores significantly improved in both the InterStim and BetterStim system groups over the treatment period. Specifically, the urination frequency (all P < 0.001), average voiding volume (all P < 0.001), and average urinary leakage (InterStim, P < 0.05; BetterStim, P < 0.01) in both groups significantly improved at different periods during treatment. At the same time, the urgency perception scale (P < 0.001) and OAB-related quality of life score (InterStim, P < 0.05; BetterStim, P < 0.01) also significantly improved. There was no significant difference in urination frequency at baseline between the two groups (P = 0.169). Urination frequency was significantly higher in the BetterStim system group than in the InterStim group during the experience period and at follow-up (P = 0.031, P = 0.006). There was no significant difference in the number of urinary leakages between the different systems at baseline (P = 0.662), although this was higher in the InterStim system group during the experience period (P = 0.016), and the difference disappeared at the last follow-up (P = 0.565). There were significant differences in baseline urgency perception scale (P = 0.001) and OAB-related quality of life score (P < 0.001) between the two groups; however, these differences were not maintained at follow-up (P = 0.81, P = 0.479). Both sacral neuromodulation systems are safe and effective in treating overactive bladder. The InterStim system may be more beneficial for patients with dry overactive bladder. Satisfactory outcomes may be achieved with the BetterStim system in patients with wet overactive bladder. However, further studies are required to confirm this finding.

show abstract

Section: Discussionmentioning

confidence: 99%

Sacral neuromodulation for overactive bladder using the InterStim and BetterStim systems

Meng

Tian

Zhang

et al. 2022

Sci Rep

View full text Add to dashboard Cite

show abstract

“…However, subsequent interventions for revision or device replacement (due to battery life) are required in 19%–36% of cases ( 74 , 75 ). Recent advancements have brought about the utilisation of rechargeable batteries with a claimed lifespan of more than 20 years, requiring recharging every 6 to 10 months ( 76 ).…”

Section: Treatmentmentioning

confidence: 99%

Faecal incontinence—a comprehensive review

Dexter,

Walshaw,

Wynn

et al. 2024

Front. Surg.

View full text Add to dashboard Cite

IntroductionFaecal incontinence (FI) is a distressing and often stigmatizing condition characterised as the recurrent involuntary passage of liquid or solid faeces. The reported prevalence of FI exhibits considerable variation, ranging from 7 to 15% in the general population, with higher rates reported among older adults and women. This review explores the pathophysiology mechanisms, the diagnostic modalities and the efficiency of treatment options up to date.MethodsA review of the literature was conducted to identify the pathophysiological pathways, investigation and treatment modalities.Result and discussionThis review provides an in-depth exploration of the intricate physiological processes that maintain continence in humans. It then guides the reader through a detailed examination of diagnostic procedures and a thorough analysis of the available treatment choices, including their associated success rates. This review is an ideal resource for individuals with a general medical background and colorectal surgeons who lack specialized knowledge in pelvic floor disorders, as it offers a comprehensive understanding of the mechanisms, diagnosis, and treatment of faecal incontinence (FI).

show abstract

“…Ook zijn bij oplaadbare systemen heroperaties minder frequent nodig: de huidige modellen beloven behoud van de batterijkwaliteit gedurende 15 jaar. Er zijn inmiddels twee soorten op de markt, van Axonics en Medtronic [36,37].…”

Section: Technische Ontwikkelingenunclassified

Update van sacrale neuromodulatie voor functiestoornissen van de lage urinewegen

et al. 2021

View full text Add to dashboard Cite

SamenvattingSacrale neuromodulatie (SNM) wordt sinds de jaren 90 van de vorige eeuw toegepast als behandeling voor therapieresistente overactieve blaas of niet-obstructieve urineretentie. In dit artikel wordt het neuromodulatiesysteem, de indicaties en het werkingsmechanisme toegelicht aan de hand van de huidige inzichten en recente publicaties. Tevens worden de nieuwe ontwikkelingen op het gebied van operatietechniek, beleid rond de ingreep en het technisch aspect besproken.

show abstract

Two‐year outcomes of the ARTISAN‐SNM study for the treatment of urinary urgency incontinence using the Axonics rechargeable sacral neuromodulation system

Abstract: Aims: Sacral neuromodulation (SNM) is a guideline-recommended treatment with proven therapeutic benefit for urinary urgency incontinence (UUI) patients.

Cited by 22 publications

References 22 publications

Sacral neuromodulation for overactive bladder using the InterStim and BetterStim systems

Sacral neuromodulation for overactive bladder using the InterStim and BetterStim systems

Faecal incontinence—a comprehensive review

Update van sacrale neuromodulatie voor functiestoornissen van de lage urinewegen

Contact Info

Product

Resources

About